Q-omics provides the consensus-scored LTF profile across patient tissues and cancer cell-line models. LTF expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LTF is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, LTF RNA expression shows 14,915 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, THCA, and LSCC as cancer lineages where LTF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LTF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LTF survival associations across molecular data types. LTF RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LTF RNA expression–survival associations across cancer types. High LTF expression shows unfavorable associations in LGG, UVM and STAD, but favorable associations in HNSC, KIRC and SARC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LTF RNA expression.
This table summarizes LTF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LTF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LTF shows lower tumor expression in THCA, KIRC, HNSC, KICH, BRCA and BLCA. The THCA box plot shows higher LTF RNA expression in normal versus tumor tissue (log2 FC = −3.675, t-test p < 0.001).
This table shows molecular features associated with LTF in patient tissues and cancer cell lines. In patient samples, LTF shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LTF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
